GlobeNewswire·Nov 12, 2026, 4:01 PM ET

Erasca Reports Third Quarter 2026 Business Updates and Financial Results

Erasca received FDA Fast Track Designation for ERAS-0015 to treat metastatic pancreatic adenocarcinoma in August 2026.
The company is advancing toward three potentially registration-enabling trials in pancreatic & lung cancers.
Updated ERAS-0015 monotherapy & nonclinical ERAS-0015/ERAS-4001 combination data will be presented at the ENA Symposium in November 2026.
Preliminary data for ERAS-4001 is expected in H2 2026, while ERAS-0015 data is anticipated in H1 2027.
Cash, cash equivalents, & marketable securities totaled $948 million as of September 30, 2026.
Erasca appointed Charles Fuchs, M.D., M.P.H. as president of R&D & David Chonzi, M.D. as senior vice president of global pharmacovigilance in August 2026.
The company completed an upsized public offering in July 2026, raising approximately $632.5 million in gross proceeds.
Phase 3 pivotal trials for ERAS-0015 are expected to initiate in first-line PDAC in 2027 & in RASm NSCLC in H2 2027 to H1 2028.
R&D expenses for the quarter ended September 30, 2026, were $47.2 million, up from $22.5 million in the same period last year.
G&A expenses for the quarter ended September 30, 2026, were $12.3 million, compared to $10.1 million in the prior year period.
The net loss for the quarter ended September 30, 2026, was $51.3 million, or $0.15 per share, compared to $30.6 million in the prior year period.
The company expects its current cash position to be sufficient to fund key upcoming milestones through 2028.